Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by National Taiwan University Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01311986
First received: March 8, 2011
Last updated: April 21, 2011
Last verified: March 2011
  Purpose

The aim of this study is to measure the serum levels of CCL17, CCL18, CCL22 and CXCL10 and their expression levels in epidermis in AD and ND patients.


Condition
Atopic Dermatitis
Nummular Eczema

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples Without DNA

Patient serum, and epidermal keratinocytes for mRNA retrieval


Estimated Enrollment: 120
Study Start Date: November 2010
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with atopic dermatitis
Patients with nummular eczema
Normal control

Detailed Description:

Atopic dermatitis(AD) is a common cutaneous inflammatory disease. The pathogenesis of atopic dermatitis involves a complex interaction between atopy and environmental protein allergens which produces Th2 immune responses with IgE formation, Th2 cells dominate in lesions of atopic dermatitis, whereas Th1 and Th2 cells co-dominate in late eczematus lesions.

Nummular dermatitis(ND) is another common cutaneous inflammatory disease. The nummular patches and papules disseminated over four extremities and less over trunk . The serum levels of Th2 chemokines(CCL17, CCL22, CCL27) are elevated in AD patients. The expression levels of these chemokines in lesional epidermis are also increased. CCL18 which is derived from APC is also increased in the serum as well as lesional skin of AD patients. In contrast, there are very few reports regarding the chemokine expression profiles in ND patients. Because erosis is a remarkable exacerbating factor for ND. The investigators hypothesize that ND is a specialized contact dermatitis induced by environmental substances. It has been known, CCL17 and CXCL10 were highly expressed in lesion of allergic contant dermatitis, whereas almost no expression of these chemokines could be detected in lesions of irritant contact dermatitis.

The aim of this study is to measure the serum levels of CCL17, CCL18, CCL22 and CXCL10 and their expression levels in epidermis in AD and ND patients. The investigators hope that the results of this study will provide useful information for clinical differential diagnosis for AD and ND as well as understanding the pathogenesis of ND.

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients with atopic dermatitis

patients with nummular eczema without atopy

Criteria

Inclusion Criteria:

  • age:20~40, atopic dermatitis, BSA>10%, no asthma
  • age:20~40, nummular patches>10, no atopy

Exclusion Criteria:

  • systemic immunosuppresive agents within 4 weeks
  • high dose topical immunosuppresive agents within 4 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01311986

Locations
Taiwan
National Taiwan University Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Hsien-Ching Chiu, MD Department of Dermatology, National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Hsien-Ching Chiu, Department of Dermatology, National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01311986     History of Changes
Other Study ID Numbers: 201006030R
Study First Received: March 8, 2011
Last Updated: April 21, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
atopic dermatitis
nummular eczema
chemokines

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on August 25, 2014